---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-022423"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:27:56.022895+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sagimet's second FASN inhibitor TVB-3567 gets IND clearance for acne

## Summary
- FDA's Division of Dermatology and Dentistry cleared IND for TVB-3567, a small molecule FASN inhibitor.
- TVB-3567 targets sebum production; FASN drives ~80% of sebum lipids in acne pathogenesis.
- First-in-human Phase 1 trial planned for 2025, randomized, double-blind, placebo-controlled.
- Building on denifanstat data, partner Ascletis showed significant lesion reduction in Phase 2 acne trial.
- Over 50 million acne patients in the US; FASN inhibition seen as significant commercial opportunity.

## SEC filing metadata
- accession: 0001104659-25-022423
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925022423/0001104659-25-022423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925022423/tm258742d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-022423
- JSON: https://secwatch.observer/filing/0001104659-25-022423.json
- Plain text: https://secwatch.observer/filing/0001104659-25-022423.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.